Development of Anti-adhesion Molecules Indicate Portfolio Diversification Opportunities

Several ongoing drug development projects signify increased reliability of patients on inflammatory bowel disease (IBD) treatment. Based on disease indication, a study published by Transparency Market Research (TMR) reported that, therapeutics for ulcerative colitis are projected to have a relatively wider patient pool than Crohn’s disease, and that their collective sales will reflect on the healthy growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market.

Numerous non-profit institutions along with the governments of various regions are found taking initiatives to educate individuals regarding IBD through campaigns and workshops, which is progressively increasing the patient base for the IBD (ulcerative colitis and Crohn’s disease) treatment market. Besides the informative approach of public organizations, privately-held pharmaceutical companies sense the lucrative landscape that the IBD treatment market is, and are making profits by addressing unmet treatment needs through the development of effective therapeutics.

In the future, the recent development of anti-adhesion molecules will serve as an open ground for market players to introduce new formulations, and target patients who fail to respond to traditional therapeutics. That being said, considering the underlying opportunities that market players are likely to explore to remain as patient-centric as possible, the TMR study projects an above-average growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market, at an estimated CAGR of ~6% during 2019-2027

inflammatory bowel disease

To know the scope of our report Get a Sample on IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market 

Retail Pharmacies to Remain Integral Aspect of Customer Acquisition Strategy

In the era where consumers tend to resonate more with online distribution channels, surprisingly, ~76% of the total sales of IBD treatment therapeutics are projected to arrive from retail pharmacies, in 2019, which was ~75% in 2018, and is likely to grow to ~78% by 2027. The limited popularity of online pharmacies narrows down to warning letters issued by the U.S. Food and Drug Administration Agency regarding potentially dangerous prescription drugs sold by some rogue online channels. However, a wide distribution network, 24X7 accessibility of retail pharmacies, and one-to-one consultation in cases of absence of primary care are the key influencers leading to high sales, implying that, a distribution partnership with these channels could amplify sales prospects.

Get a glimpse of the in-depth analysis through our Report Brochure

North America to Remain Established IBD Treatment Market

The IBD (ulcerative colitis and Crohn’s disease) treatment market in North America is driven by continuous development led by key pharmaceutical companies, as well as increased government funding to underpin the development of better therapeutics. Key companies operating in the region are focusing on the development of branded drugs, while trends reported in TMR’s study suggest that, developing countries in Asia Pacific will witness an increase in the development of biosimilar products. In order to ensure the efficiency of these drugs, several countries such as Australia, Japan, India, China, South Korea, and Malaysia are establishing regulatory norms and testing standards for the approval of biosimilar products.

Frequent Patent Expiration in Established Markets - What Should Market Players Expect?

Irrespective of the severity of Crohn’s disease, corticosteroids are deemed effective in inducing disease remission. However, these drugs fall short in preventing flare-ups. To add to that, side-effects related to their long-term use implies that, these drugs cannot be used as continuous therapy, and their patent is likely to expire in 2020.

Besides this, even Remicade of Johnson & Johnson’s and Humira of Adalimumab faced patent expiration. Frequent instances of patent expiration are unfolding sales opportunities for generic products, and several players are scrambling toward the development of these drugs. Zydus Cadila, a key player, accounting for ~40% share in the ulcerative treatment market, illustrated this shift in 2017. The company announced the launch of a generic version of Lialda® in the U.S. In 2018, Teva Pharmaceutical Industries Ltd. also announced the addition of a generic version of Lialda® to its generic portfolio.

The growing popularity of generic drugs is projected to instigate more players in the IBD (ulcerative colitis and Crohn’s disease) treatment market to introduce generic versions of branded drugs in the future. In addition, advanced versions of generic drugs, biosimilars, are coming down the pike in the IBD treatment market, which is likely to upkeep the interest of market players toward the introduction of new products.

inflammatory bowel disease segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Take on IBD Treatment Market Growth

Though analysts of the TMR study infer from the analysis, that the IBD (ulcerative colitis and Crohn’s disease) treatment market will grow at an above-average pace, they opine that, high-cost concerns could hamper the sales of therapeutics. However, the introduction of reimbursement plans to cushion healthcare expenditures will lead to positive sentiments among patients toward effective treatment.

Investments in TNF inhibitors will help achieve high RoI, since physicians tend to prescribe these drugs for the treatment of moderate to severe ulcerative colitis, while potential opportunity through the development of anti-adhesion molecules will boost the adoption of integrin antagonists.

Analysts recommend that, channelizing sales through all the distribution channels – online, retail, hospital pharmacies - will help ease the efforts of companies as far as acquisition and retention of consumer base is concerned.

Global IBD (Ulcerative Colitis and Crohn's Disease) Treatment Market: Overview

  • The global IBD (ulcerative colitis and Crohn's disease) treatment market was valued at ~US$ 15.5 Bn in 2018 and is projected to expand at a CAGR of ~6% from 2019 to 2027.
  • Rise in IBD patient pool, approval of new biologic drugs for IBD, novel drugs pipeline, and increase in access to IBD treatment in developing markets are anticipated to fuel the growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market.
  • Inflammatory bowel disease is a group of gastrointestinal inflammatory diseases that mainly comprises of ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long-term chronic as well as severe inflammation in gastrointestinal tract, without any known cause. Ulcerative colitis disease mainly affects the inner lining of the large intestines, and causes inflammation and sores in the colon and rectum. Ulcerative colitis is a more commonly observed disease than Crohn’s disease. Unlike ulcerative colitis, Crohn’s disease is not restricted to only the large intestines and rectum. It can affect any part of the gastrointestinal tract, starting from the mouth to the small intestine and anus. The common symptoms of IBD include chronic pain and cramps in the abdomen, persistent diarrhea, occasional rectal bleeding, and fever. The exact cause of inflammatory bowel disease is not well understood, and the high prevalence and incidence rates of these diseases have been observed in developed countries.
  • The global inflammatory bowel disease treatment market is projected to be driven by new product development and approvals, growing inclination toward the use of biologic and biosimilar drugs, and high prevalence and incidence of IBD in Western countries. Biopharmaceutical companies have made significant investments in R&D activities, and a large number of pipeline products are in different stages of clinical approvals, which are likely to commercialize during the forecast period.
  • According to the Center for Disease Control and Prevention (CDC), in 2015, approximately 3.1 million people (1.3% of the entire population) in the U.S. were diagnosed with either Crohn’s disease or ulcerative colitis. It is estimated that, each year, around 70,000 new cases of IBD are diagnosed in the U.S. The hospitalization rate of the secondary diagnosed population with IBD has significantly increased from 44.2 to 59.7 per 100,000 during 2003 to 2013. In Europe, it is estimated that, around 2.5 million to 3 million people are affected by inflammatory bowel diseases each year. The highest incidence and prevalence of IBD is observed in Scandinavia and the U.K. The incidence of Crohn’s disease in Europe ranges from 0.5 to 10.6 cases per 100,000 people per year, whereas, the incidence for ulcerative colitis ranges from 0.9 to 24.3 per 100,000 people per year. Increase in the number of IBD patients is expected to drive the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. 

Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market: Segment Analysis

  • The global IBD (ulcerative colitis and Crohn’s disease) treatment market has been segmented based on drug class, disease indication, distribution channel, and region
  • In terms of drug class, the global IBD treatment market has been categorized into TNF inhibitors, aminosalicylates, integrin antagonists, corticosteroids, and others. The TNF inhibitors segment is projected to lead the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. The high market share of the TNF inhibitors segment in the global IBD (ulcerative colitis and Crohn’s disease) treatment market can be attributed to superior efficacy and safety of drugs in this class in the treatment of IBD. Moreover, the promising pipeline of drugs in the TNF inhibitors segment, rise in the adoption of biologic drugs for the treatment of IBD, and high clinical R&D budgets contributed to large share of the TNF inhibitors segment in 2018, in the global IBD treatment market.
  • Based on disease indication, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been divided into ulcerative colitis and Crohn’s disease. The ulcerative colitis segment in the global IBD treatment market accounted for the largest share in 2018, and the trend is expected to continue during the forecast period. Increase in the diagnosis of ulcerative colitis, relapse of the disease within five years, and increased awareness among the population are likely to drive the segment in the global IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period.
  • In terms of distribution channel, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment dominated the global IBD treatment market in 2018, owing to the higher sales of biologics through retail pharmacies in developed countries, including the U.S. and Canada. 

Global IBD Treatment Market: Regional Segmentation

  • In terms of region, the global IBD (ulcerative colitis and Crohn’s disease) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America dominated the global IBD (ulcerative colitis and Crohn’s disease) treatment market, and is projected to gain market share by the end of 2027. The region’s dominance in the global IBD treatment market is attributed to the high prevalence & increase in incidence of ulcerative colitis and Crohn’s disease in the U.S. and Canada, well-established healthcare facilities, and high risk of lifestyle-related factors. Additionally, robust product pipeline of key players is projected to boost the growth of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in the region.
  • Asia Pacific is projected to be the fastest-growing IBD (ulcerative colitis and Crohn’s disease) treatment market during the forecast period. Japan dominated the IBD treatment market in the region, whereas, the IBD (ulcerative colitis and Crohn’s disease) treatment market in China is estimated to expand at a high CAGR during the forecast period.
  • The IBD (ulcerative colitis and Crohn’s disease) treatment markets in Latin America and Middle East & Africa are likely to expand at decent CAGRs, owing to an increase in the IBD patient pool and focus of manufacturers on the development of novel therapeutics. 

Global IBD Treatment Market: Major Players

  • Companies such as AbbVie, Inc., Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson) etc., accounted for a major share in the global IBD (ulcerative colitis and Crohn’s disease) treatment market in 2018. Other global players operating in the global IBD (ulcerative colitis and Crohn’s disease) treatment market include Allergan plc, Bausch Health Companies Inc., Takeda Pharmaceutical Company Limited, Novartis AG, UCB Inc., and Biogen, Inc.
  • These players are focused on adopting organic and inorganic growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs in order to be competitive in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market - Scope of the Report

TMR’S report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global IBD (ulcerative colitis and Crohn’s disease) treatment market for the period of 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global IBD treatment market for the forecast period.

The report has been prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global IBD treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, which include disease prevalence: IBD (ulcerative colitis and Crohn’s disease) globally, IBD (ulcerative colitis and Crohn’s disease) treatment pipeline analysis, and major deals and strategic alliances analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

The report delves into the competitive landscape of the global IBD (ulcerative colitis and Crohn’s disease) treatment market. Key players operating in the global IBD treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overviews, financial standings, recent developments, and SWOT are some of the attributes of the players profiled in the global IBD (ulcerative colitis and Crohn’s disease) treatment market report.

Key Questions Answered in Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Report

  • What is the sales/revenue expected to be generated by IBD (ulcerative colitis and Crohn’s disease) treatment products across all the regions during the forecast period?
  • What are the key trends in the IBD (ulcerative colitis and Crohn’s disease) treatment market?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue, globally, in 2027, and which product segment will expand at the fastest CAGR during the forecast period?

Global IBD Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global IBD (ulcerative colitis and Crohn’s disease) treatment market begins with an overview of the said market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of this study and healthcare compliances laid down by accredited agencies in the purview of research in the global IBD (ulcerative colitis and Crohn’s disease) treatment market. It is followed by a market introduction, market dynamics, and an overview of the global IBD treatment market, which includes TMR’s analysis of the market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights have been provided to understand the Y-o-Y trends of the IBD (ulcerative colitis and Crohn’s disease) treatment market. The next section of the global IBD (ulcerative colitis and Crohn’s disease) treatment report highlights the USPs, including disease prevalence, globally, treatment pipeline analysis, and major deals & strategic alliance analysis in the global IBD (ulcerative colitis and Crohn’s disease) treatment market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key IBD (ulcerative colitis and Crohn’s disease) treatment players has been mapped to ascertain the size of the global IBD (ulcerative colitis and Crohn’s disease) treatment market in terms of value. The forecasts presented here assess the total revenue generated in the IBD (ulcerative colitis and Crohn’s disease) treatment market. In order to provide an accurate forecast, we initiated by sizing up the current IBD (ulcerative colitis and Crohn’s disease) treatment market with the help of the parent market.

Global Inflammatory Bowel Disease Treatment Market is segmented as given below:

Drug Class

  • TNF Inhibitors
  • Aminosalicyclates
  • Immunomodulators
  • Corticosteroids

Disease Indication

  • Ulcerative Colitis
  • Crohn’s Disease

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography

 

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Inflammatory Bowel Disease

Buy Now